利用循环肿瘤细胞鉴定去势抵抗性前列腺癌耐药机制的前景:上皮细胞到间质细胞的转化是关键因素吗?

IF 2.3 Q3 ONCOLOGY Prostate Cancer Pub Date : 2020-03-30 eCollection Date: 2020-01-01 DOI:10.1155/2020/7938280
Tanzila Khan, Kieran F Scott, Therese M Becker, John Lock, Mohammed Nimir, Yafeng Ma, Paul de Souza
{"title":"利用循环肿瘤细胞鉴定去势抵抗性前列腺癌耐药机制的前景:上皮细胞到间质细胞的转化是关键因素吗?","authors":"Tanzila Khan,&nbsp;Kieran F Scott,&nbsp;Therese M Becker,&nbsp;John Lock,&nbsp;Mohammed Nimir,&nbsp;Yafeng Ma,&nbsp;Paul de Souza","doi":"10.1155/2020/7938280","DOIUrl":null,"url":null,"abstract":"<p><p>Prostate cancer (PCa) is initially driven by excessive androgen receptor (AR) signaling with androgen deprivation therapy (ADT) being a major therapeutic approach to its treatment. However, the development of drug resistance is a significant limitation on the effectiveness of both first-line and more recently developed second-line ADTs. There is a need then to study AR signaling within the context of other oncogenic signaling pathways that likely mediate this resistance. This review focuses on interactions between AR signaling, the well-known phosphatidylinositol-3-kinase/AKT pathway, and an emerging mediator of these pathways, the Hippo/YAP1 axis in metastatic castrate-resistant PCa, and their involvement in the regulation of epithelial-mesenchymal transition (EMT), a feature of disease progression and ADT resistance. Analysis of these pathways in circulating tumor cells (CTCs) may provide an opportunity to evaluate their utility as biomarkers and address their importance in the development of resistance to current ADT with potential to guide future therapies.</p>","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2020 ","pages":"7938280"},"PeriodicalIF":2.3000,"publicationDate":"2020-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/7938280","citationCount":"12","resultStr":"{\"title\":\"The Prospect of Identifying Resistance Mechanisms for Castrate-Resistant Prostate Cancer Using Circulating Tumor Cells: Is Epithelial-to-Mesenchymal Transition a Key Player?\",\"authors\":\"Tanzila Khan,&nbsp;Kieran F Scott,&nbsp;Therese M Becker,&nbsp;John Lock,&nbsp;Mohammed Nimir,&nbsp;Yafeng Ma,&nbsp;Paul de Souza\",\"doi\":\"10.1155/2020/7938280\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Prostate cancer (PCa) is initially driven by excessive androgen receptor (AR) signaling with androgen deprivation therapy (ADT) being a major therapeutic approach to its treatment. However, the development of drug resistance is a significant limitation on the effectiveness of both first-line and more recently developed second-line ADTs. There is a need then to study AR signaling within the context of other oncogenic signaling pathways that likely mediate this resistance. This review focuses on interactions between AR signaling, the well-known phosphatidylinositol-3-kinase/AKT pathway, and an emerging mediator of these pathways, the Hippo/YAP1 axis in metastatic castrate-resistant PCa, and their involvement in the regulation of epithelial-mesenchymal transition (EMT), a feature of disease progression and ADT resistance. Analysis of these pathways in circulating tumor cells (CTCs) may provide an opportunity to evaluate their utility as biomarkers and address their importance in the development of resistance to current ADT with potential to guide future therapies.</p>\",\"PeriodicalId\":20907,\"journal\":{\"name\":\"Prostate Cancer\",\"volume\":\"2020 \",\"pages\":\"7938280\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2020-03-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1155/2020/7938280\",\"citationCount\":\"12\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Prostate Cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2020/7938280\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2020/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prostate Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2020/7938280","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 12

摘要

前列腺癌(PCa)最初是由过多的雄激素受体(AR)信号驱动的,雄激素剥夺疗法(ADT)是治疗前列腺癌的主要治疗方法。然而,耐药性的发展对一线和最近开发的二线ADTs的有效性都是一个重大限制。因此,有必要在其他可能介导这种耐药性的致癌信号通路的背景下研究AR信号。本综述的重点是转移性去势抵抗性前列腺癌中AR信号通路、众所周知的磷脂酰肌醇-3激酶/AKT通路以及这些通路的新兴介质Hippo/YAP1轴之间的相互作用,以及它们参与上皮-间质转化(EMT)的调节,EMT是疾病进展和ADT抵抗的一个特征。对循环肿瘤细胞(CTCs)中这些通路的分析可能提供一个机会来评估它们作为生物标志物的效用,并解决它们在当前ADT耐药性发展中的重要性,并有可能指导未来的治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
The Prospect of Identifying Resistance Mechanisms for Castrate-Resistant Prostate Cancer Using Circulating Tumor Cells: Is Epithelial-to-Mesenchymal Transition a Key Player?

Prostate cancer (PCa) is initially driven by excessive androgen receptor (AR) signaling with androgen deprivation therapy (ADT) being a major therapeutic approach to its treatment. However, the development of drug resistance is a significant limitation on the effectiveness of both first-line and more recently developed second-line ADTs. There is a need then to study AR signaling within the context of other oncogenic signaling pathways that likely mediate this resistance. This review focuses on interactions between AR signaling, the well-known phosphatidylinositol-3-kinase/AKT pathway, and an emerging mediator of these pathways, the Hippo/YAP1 axis in metastatic castrate-resistant PCa, and their involvement in the regulation of epithelial-mesenchymal transition (EMT), a feature of disease progression and ADT resistance. Analysis of these pathways in circulating tumor cells (CTCs) may provide an opportunity to evaluate their utility as biomarkers and address their importance in the development of resistance to current ADT with potential to guide future therapies.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Prostate Cancer
Prostate Cancer ONCOLOGY-
CiteScore
2.70
自引率
0.00%
发文量
9
审稿时长
13 weeks
期刊介绍: Prostate Cancer is a peer-reviewed, Open Access journal that provides a multidisciplinary platform for scientists, surgeons, oncologists and clinicians working on prostate cancer. The journal publishes original research articles, review articles, and clinical studies related to the diagnosis, surgery, radiotherapy, drug discovery and medical management of the disease.
期刊最新文献
Investigating the Relationship of G-137C, C-607A, and A-1447G Polymorphisms in the Promoter of IL-18 and CXCL10 Inflammatory Genes with Prostate Cancer in an Iranian Population. Evaluation of Second-Line Treatment for Castration-Resistant Prostate Cancer following the Administration of Upfront Androgen Receptor Signaling Inhibitors. Health-Related and Psychosocial Factors Associated with Prostate Cancer Stage at Diagnosis among Males Participating in Alberta’s Tomorrow Project Cognitive Dysfunction in Patients Treated with Androgen Deprivation Therapy: A Multimodality Functional Imaging Study to Evaluate Neuroinflammation. Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1